IP Library Granted Patent US 10,738,308
Granted Patent B2
US 10,738,308 · App. 15/863,578 · Granted Aug 11, 2020

Short interfering nucleic acid (siNA) molecules containing a 2′ internucleoside linkage (3dT)

Inventors: Wonsuk Chang (Kenilworth, NJ); Erin N. Guidry (Kenilworth, NJ); Matthew G. Stanton (Rahway, NJ); Daniel Zewge (Rahway, NJ)
Assignee: SIRNA THERAPEUTICS, INC.
C12N15/113C07H19/10C07H21/00C07H21/02C07H21/04C12N15/111C12N2310/11C12N2310/14C12N2310/319
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,738,308
App. No.
15/863,578
Granted
Aug 11, 2020
Kind
B2
Abstract

The present invention relates to RNAi molecules, and compositions thereof, comprising a 2′ internucleoside linkage connecting the nucleotide at position 1 and the nucleotide at position 2 at the 5′ end of the antisense strand. Specifically, the invention relates to single- and double-stranded short interfering nucleic acid (siNA) molecules that are capable of mediating RNA interference comprising 5′ modified nucleotides that comprise, among other potential modifications, a 2′ internucleoside linkage. The invention further relates to 5′ modified nucleotides used as reagents to generate the RNAi molecules of the invention and methods of using the disclosed RNAi molecules.

Claims (14)

1. A double stranded short interfering nucleic acid (siNA) molecule capable of mediating RNA interference, comprising an antisense strand that is complementary to a nucleic acid target, wherein said antisense strand comprises a modified nucleotide at the first nucleotide position, wherein the modified nucleotide comprises a sugar ring, wherein carbon 5 of the sugar ring contains the following substituent (═CH)—P(═O)(OH) 2 , and wherein the modified nucleotide is a 2′-O-methyl nucleotide.

2. The short interfering nucleic acid of claim 1 , wherein the modified nucleotide comprises the following structure:

3. The siNA molecule of claim 1 , wherein the modified nucleotide comprises a heterocyclic base chosen from uracil, thymine, cytosine, 5-methylcytosine, adenine, or guanine.

4. The siNA molecule of claim 1 , wherein the modified nucleotide comprises an internucleo side linking group linking the modified nucleotide to the sugar moiety of an adjacent nucleotide of the siNA molecule, and wherein the internucleoside linking group is chosen from a phosphodiester internucleoside linking group or a phosphorothioate internucleoside linking group.

5. The siNA molecule of claim 1 , wherein the siNA molecule comprises one or more additional chemically-modified nucleotides.

6. The siNA molecule of claim 5 , wherein the one or more of the additional chemically-modified nucleotides is a 2′-O-methyl nucleotide.

7. The siNA molecule of claim 6 , wherein the one or more of the 2′-O-methyl nucleotides comprises a phosphorothioate internucleoside linking group.

8. The siNA molecule of claim 1 , which further comprises a conjugate.

9. The siNA molecule of claim 8 , wherein the conjugate comprises N-acetylgalactosamine.

10. The siNA molecule of claim 8 , wherein the conjugate comprises a tetra-N-acetylgalactosamine aminohexyl moiety.

11. The siNA molecule of claim 1 , which further comprises an inverted abasic nucleotide.

12. The siNA molecule of claim 1 , which comprises a sense strand, wherein the antisense strand and the sense strand are each independently 15 to 30 nucleotides in length.

13. The siNA molecule of claim 1 , further comprising one or more 3′-overhanging nucleotides on one or both strands.

14. A composition comprising the siNA molecule of claim 1 in a pharmaceutically acceptable carrier or diluent.

Assignments (3)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2020
From: CHANG, WONSUK; GUIDRY, ERIN N.; STANTON, MATTHEW G.; ZEWGE, DANIEL
To: MERCK SHARP & DOHME CORP.
Reel/Frame 052979/0129 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2020
From: SIRNA THERAPEUTICS, INC.
To: SIRNA THERAPEUTICS, INC.
Reel/Frame 052979/0136 →
Continuity (3)
Continuation 14769361
Provisional Application 61767837 · Feb 22, 2013
Related Publication 20180265869A1 · Sep 20, 2018